Microbot Medical Merges with StemCells
Microbot Medical Ltd., an Israel-based medical device company that specializes in the research, design, development and commercialization of micro-robotics-assisted medical technologies, has merged with StemCells Inc. (NASDAQ: STEM), a biotech firm that engages in the research, development, and commercialization of stem cell-based therapeutics for the treatment of central nervous system diseases. For StemCells, this merger is a strategic alternative to its failed Phase 2 clinical study of human neural stem cells in chronic spinal cord injuries. The combined company will pursue the development of robotics-based medical devices for the treatment of cerebrospinal fluid and gastrointestinal... Read More »Cantel Medical Adds Dental to Its Healthcare Disposables Segment
With five acquisitions in the infection prevention/disposables market since 2014, Cantel Medical (NYSE: CMN) is on a roll. The company, which provides infection prevention and control product and services, just announced its second medical device deal this year, buying Accutron Inc., a privately-held manufacturer of nitrous oxide delivery systems and single-use nasal masks. The $52.5 million acquisition will expand the dental portfolio of Crosstex International, Cantel’s Healthcare Disposables segment, adding a branded, single-use disposable product line. The acquisition marks Cantel’s entry into the dental equipment market. In February 2016, Cantel acquired the Sterility... Read More »June 2016 M&A Results Show Strength
Uncertainty is the hobgoblin of the merger and acquisition markets, and the month of June was a high point (or low point, depending on your perspective) for anxiety in global financial markets. Still, the healthcare deals kept rolling in. Our preliminary total for June 2016 stands at 115 transactions, exactly equal with the same month a year ago. Compared with May’s total of 141 deals, though, June’s total does look as if someone is applying the brakes. It takes 12 months to make a year, though, and one month’s results do not create a trend. The digital health sector turned in the strongest gain compared with June 2015, when only two deals were announced. This June, 22 deals were announced... Read More »Q2:16 Results Defy Brexit and Other Uncertainties
You’ve seen the headlines: Global mergers and acquisitions slid in the first half of 2016, as did the combined value. The number of middle market deals completed in the second quarter fell to levels not seen since 2009. Buyers are walking away from targets that could be affected by sudden changes in tax regulations. It’s all thanks to Brexit and the U.S. presidential election. Then there’s the healthcare market. Deal volume actually increased compared with the previous quarter in 2016, and the same quarter a year ago. Deal volume for Q2:16 reached 396 announced transactions, up 11% versus Q1:16’s 358 deals, and 15% higher than last year’s 344 deals in the second quarter. For the first half... Read More »Cells Sell…to GE At Least
GE Healthcare, a subsidiary of GE (NYSE:GE), recently announced that it had acquired a privately-held Sweden-based company, Biosafe Group SA, a developer, manufacturer and supplier of products for cell processing in the areas of adult stem cell banking. The combined biological, engineering and industrial capabilities should advance cell therapy and cellular immunotherapy GE’s interest in cellular research is not new. In January 2016, GE Ventures completed a $31.5 million co-investment with the Canadian government to create the BridGE@CCRM Cell Therapy Centre of Excellence in order to promote new technologies for the product of new cellular therapies in Toronto. Then, in April, GE Ventures... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
